If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
==== I. Lipophilic Drugs ==== Microbubbles can facilitate the local targeting of hydrophobic drugs through the incorporation of these agents into the microbubble lipid shell. This encapsulation technique reduces systemic toxicity, increases drug localization, and improves the solubility of hydrophobic drugs. For increased localization, a targeting ligand can be appended to the exterior of the microbubble. This improves treatment efficacy. One drawback of the lipid-encapsulated microbubble as a drug delivery vehicle is its low payload efficacy. To combat this, an oil shell can be incorporated to the interior of the lipid monolayer to enhance payload efficacy.
== Gameplay == In Episode One, where Alyx's role as a companion is expanded upon, her artificial intelligence (AI) was designed specifically for co-operative play to complement the player's abilities. The developers described Alyx's programming for Episode One as a "personality code" as opposed to an "AI code", emphasizing the attention they gave to create a unique and believable companion. In addition, she was specially programmed to avoid performing too many mechanical or repetitive actions, such as repeating lines of dialogue or performing certain routines in combat situations. Examples of this co-operative gameplay include combat in underground levels, where the player can use their flashlight to help Alyx spot and kill oncoming enemies, thereby conserving their own ammunition. Similarly, Alyx will often take up strategic positions and provide covering fire to keep the player safe while they travel to a certain area or perform certain actions.
=== Phase 2 === AD-036 – undefined mechanism of action [6] Atomoxetine/mineralocorticoid receptor antagonist (atomoxetine/antimineralocorticoid; AD-113) – combination of atomoxetine (norepinephrine reuptake inhibitor) and a mineralocorticoid receptor antagonist [7] Atomoxetine/trazodone (trazodone/atomoxetine; AD-504) – combination of atomoxetine (norepinephrine reuptake inhibitor) and trazodone (various actions/hypnotic) [8] BAY-2586116 – potassium channel blocker [9] CX-1739 – ampakine (AMPA receptor positive allosteric modulator) [10] Dronabinol low-dose (tetrahydrocannabinol; THC; PP-001) – cannabinoid CB1 and CB2 receptor agonist [11] Dronabinol/palmidrol (SCI-110; THX-OSA01; THX-RS01; THX-110; THX-TS01; THC/PEA) – combination of dronabinol (THC; cannabinoid receptor agonist) and palmidrol (palmitoylethanolamine (PEA); various actions) [12] Lorundrostat (MLS-101; MT-4129) – aldosterone synthase (CYP11B2) inhibitor [13] Phentermine/topiramate (Qnexa; Qsiva; Qsymia; topiramate/phentermine; VI-0521) – combination of phentermine (norepinephrine releasing agent) and topiramate (various actions) [14] Research programme: Sleep disordered breathing therapeutics - Shinogi-Apnimed Sleep Science – undefined mechanisms of action [15] SASS-001 – purinergic P2X3 receptor antagonist [16] Sivopixant (S-600918) – purinergic P2X3 receptor antagonist [17] Sulthiame (SASS-002; sulthiame; Sultia; sultiame) – carbonic anhydrase inhibitor [18] [19] Trazodone/viloxazine (AD-816; viloxazine/trazodone) – combination of trazodone (various actions/hypnotic) and viloxazine (norepinephrine reuptake inhibitor) [20]
In 2013, Lieutenant colonel Riho Ühtegi wrote: "to this day it is relatively difficult to obtain information about what really happened at any given moment in 2008. [...] Nevertheless, even in June 2008 all the signs showed that even if war were to erupt, it would happen in Abkhazia. [...] The situation changed in June. [...] The Ossetians attacked the Georgian-populated villages in South Ossetia, which was met with Georgian mortar fire from behind the line of control. [...] Indeed, considering the complicated situation in South Caucasus in the summer of 2008, it is difficult to say exactly who started the war. In fact – we should first agree upon how we define starting a war. [...] As far as provocations are concerned, [...] the Russian side or rather the Ossetians with support from the Russian forces conducted a multitude of provocations during the summer of 2008, which led to the war. [...] The Russian analysts were obviously able to assess the international situation adequately and calculated that should Georgia send its regular forces to attack the newly independent South Ossetia and should Russia react to it with a military counterstrike, it would not cause a war between great powers, because first there will be a dispute as to who the aggressor is – Russia or Georgia itself."
Weighted Companion Cubes are variants of Weighted Storage Cubes that are used in the testing chambers. They are differentiated from regular Storage Cubes with small pink hearts on its external surface, instead of an Aperture Science logo. In Portal, during test chamber 17, Chell is given a Weighted Companion Cube by GLaDOS, told by her that it will be her faithful companion for the duration of the test. Chell must use the Cube to complete the chamber, at which point GLaDOS requires her to incinerate the Cube before being able to progress further. The requirement to incinerate the companion cube originates from test-play of Portal, during which players brought their companion cube with them to later levels, with unexpected impact on game play. Another Companion Cube is seen at the end of the game, standing next to the cake. In Portal 2, redesigned Weighted Companion Cubes appear in test chamber 7 in chapter 2. GLaDOS fizzles two of them at the start of the test to annoy Chell. Chell is given the option to take a Weighted Companion Cube with her at the end of the test, but if Chell does this, GLaDOS fizzles the Companion Cube before Chell can enter the lift leading to the next test chamber. A Companion Cube with the old design, supposedly the one from Portal, appears at the very end of the game, as it is ejected, charred and singed, from the shed (possibly at ground level) shortly after Chell's departure. Companion Cubes are also mentioned a lot in the Ratman dens in Portal. In the Lab Rat comic, Ratman is also accompanied by a Companion Cube, which he imagines talks to him.
Sources: en.wikipedia.org
Furthermore, the nitrogen atom may be replaced by a phosphorus, arsenic, or antimony atom (the heavier nonmetallic pnictogens), creating a phosphonium (PH+4) or arsonium (AsH+4) cation that can itself be substituted similarly; while stibonium (SbH+4) itself is not known, some of its organic derivatives are characterised.
=== Combinations === Analgesics are frequently used in combination, such as the paracetamol and codeine preparations found in many non-prescription pain relievers. They can also be found in combination with vasoconstrictor drugs such as pseudoephedrine for sinus-related preparations, or with antihistamine drugs for people with allergies. While the use of paracetamol, aspirin, ibuprofen, naproxen, and other NSAIDs concurrently with weak to mid-range opioids (up to about the hydrocodone level) has been said to show beneficial synergistic effects by combating pain at multiple sites of action, several combination analgesic products have been shown to have few efficacy benefits when compared to similar doses of their individual components. Moreover, these combination analgesics can often result in significant adverse events, including accidental overdoses, most often due to confusion that arises from the multiple (and often non-acting) components of these combinations.
Food noise is persistent and intrusive thoughts about food even when food security is not under threat. Although research is still in the early phase, definitions of food noise have emerged, and evidence suggests that food noise is distinct from hunger, food addiction, and food preoccupation. Instead, patients experiencing food noise report constantly ruminating about eating – when to eat, whether they are eating the right types of foods, or whether they are eating the right amount – or having self-recriminating thoughts about their relationship with food. These thoughts have a high cognitive burden and can cause distress, and it has been suggested that food noise may be a reason some people struggle to lose weight. For example, according to WW International, persistent food-related thoughts can make it difficult to adhere to a nutrition or exercise plan and make healthy food choices.
=== Archaeobotanical record and ruderal habitat === The interaction between the Moche and this wild species is supported by its ecological behavior and archaeobotanical findings in the La Libertad Region. Solanum pimpinellifolium behaves as a ruderal plant, proliferating naturally and constantly along the edges of irrigation canals, ditches, and humid depressions built by pre-Hispanic agricultural engineers. Contemporary botanical and archaeological inventories have recorded stable populations of this wild tomato growing directly over the cultural contexts of major Moche political-religious centers, such as the El Brujo Arqueological Complex (in the Chicama Valley) and near the Huaca del Rosario (in Magdalena de Cao). This resource holds high scientific and historical value because Peru is a key center of origin for the tomato, hosting 14 of the world's 17 tomato species. Research by Peru's Ministry of the Environment indicates that roughly 90% of the genes in modern commercially cultivated tomatoes worldwide originate from these wild Andean relatives, which contributed high natural sugar levels and lycopene content to ancient diets.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.